Biotech · Private company
Gemini Therapeutics, Inc.
Track this companyFree. Adds Gemini Therapeutics, Inc. to your Dealase workspace and tells you when its record changes.
Clinical trials30 recruiting or active
Pipeline programs4From trials and the company's site
Disclosed deals0None found yet
Cash runwayNot availablePrivate: no SEC financials
Pipeline4
- AfliberceptPhase 2 · Neovascular Age-related Macular DegenerationClinicalTrials.gov · fetched Nov 12, 2026
- GEM103Phase 2 · Dry Age-related Macular DegenerationClinicalTrials.gov · fetched Nov 12, 2026
- GEM103Phase 2 · Neovascular Age-related Macular DegenerationClinicalTrials.gov · fetched Nov 12, 2026
- ShamPhase 2 · Neovascular Age-related Macular DegenerationClinicalTrials.gov · fetched Nov 12, 2026
Clinical trials3
- A Multiple Dose Study of Repeat Intravitreal Injections of GEM103 in Neovascular Age-related Macular DegenerationPHASE2 · TERMINATED · started Dec 29, 2020ClinicalTrials.gov NCT04684394 · fetched Nov 12, 2026
- A Multiple Dose Study of Repeat Intravitreal Injections of GEM103 in Dry Age-related Macular DegenerationPHASE2 · TERMINATED · started Jul 30, 2020ClinicalTrials.gov NCT04643886 · fetched Nov 12, 2026
- First in Human Study to Evaluate the Safety and Tolerability of GEM103 in Geographic Atrophy Secondary to Dry Age Related Macular DegenerationPHASE1 · COMPLETED · started Dec 19, 2019ClinicalTrials.gov NCT04246866 · fetched Nov 12, 2026